The Brand Name PACLITERO Has Generic Salt :: PACLITAXEL 

PACLITERO  Is From Company HETERO HC. Priced :: Rs. 2100

PACLITERO have PACLITAXEL is comes under Sub class Anti Neoplastic Agents of  Main Class Anti Neoplastic Agents

Main Medicine Class:: Anti Neoplastic Agents  Sub Medicine Class :: Anti Neoplastic Agents 

Indications for Drugs ::

Ovarian carcinoma, Breast cancer, Lung cancer, Kaposi’s sarcoma

Drug Dose ::

Adult: IV Ovarian carcinoma Primary treatment: 135 mg/m2, followed by cisplatin. Repeat 3 wkly. Secondary treatment: As single agent: 135 or 175 mg/m2 3 wkly. Breast cancer As adjunct therapy, 2nd line monotherapy or 1st line treatment w/ trastuzumab: 175 mg/m2 3 wkly for 4 courses. W/ trastuzumub, give dose one day after 1st dose of trastuzumab or immediately after subsequent doses if tolerated. 1st line treatment w/ doxorubicin: 220 mg/m2 3 wkly, give dose 24 hr after doxurubicin. Advanced non-small cell lung cancer 135 mg/m2 over 24 hr, followed by cisplatin. Repeat 3 wkly. AIDS-related Kaposi’s sarcoma 135 mg/m2 3 wkly.

Contraindication ::

History of hypersensitivity (especially macrogol glycerol ricinolate). Patients with baseline neutropenia of <1500 cells/mm3 (<1000 cells/mm3 for kaposi's sarcoma). Pregnancy and lactation. In kaposi's sarcoma, contraindicated in patients with concurrent, serious, uncontrolled infections. Drug Precautions ::

Bone marrow suppression during therapy. Monitor cardiac function if conduction abnormalities result. Premedicaton (with corticosteroid, antihistamine and histamine H2-receptor antagonist) may be required to reduce risk of hypersensitivity reaction. Discontinue, if severe reactions e.g. hypotension, dyspnoea, angioedema or urticaria occur. Caution in patients with moderate hepatic impairment. Monitor for reactions of admin. Safety and efficacy in paediatric patients have not been established. Administer before platinum derivatives (cisplatin, carboplatin) if used in combination. Hazardous agent; use appropriate precautions for handling and disposal.

Drug Side Effects ::

Neutropenia, leukopenia, thrombocytopenia, anaemia, bleeding; hypersensitivity reactions (dyspnoea, flushing, chest pain, tachycardia, rash, hypotension, hypertension); bradycardia, abnormal ECG; neurotoxicity (mainly peripheral neuropathy), myalgia, arthralgia; nausea, vomiting, diarrhoea; severe mucositis, alopecia; rarely hepatic necrosis and encephalopathy, inj site reactions e.g. erythema, tenderness, skin discolouration, swelling; interstitial pneumonitis; infections (mainly UTIs and upper respiratory tract); mucosal inflammation, severe elevation in LFTs (aspartate aminotransferase and alkaline phosphatase). Potentially Fatal: Infections and infestations leading to death e.g. pneumonia and peritonitis.

Pregnancy category ::

4

Drug Mode of Action ::  

Paclitaxel promotes microtubule formation by enhancing the action of tubulin dimers, stabilising existing microtubules and preventing their disassembly, thereby disrupting normal cell division in the late G2 mitotic phase of the cell cycle. This results in the inhibition of cell replication.

Drug Interactions ::

Myelosuppression was more profound when given after cisplatin than with the alternate sequence (e.g., paclitaxel before cisplatin). CYP2C8 inducers e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, rifapentine, and secobarbital may reduce levels or effects. CYP2C8 inhibitors e.g. gemfibrozil, ketoconazole, montelukast, and ritonavir may increase levels or effects. CYP3A4 inducers e.g. aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins may decrease the levels or effects. CYP3A4 inhibitors e.g. azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil may increase levels or effects. May increase anthracycline (eg doxorubicin, epirubicin) levels or toxicity; admin of anthracycline at least 24 hr prior to paclitaxel may reduce interaction. May decrease the absorption of cardiac glycosides (may only affect digoxin tablets); levels should be monitored.